IP Library › Granted Patent US 10,633,659
Granted Patent B2
US 10,633,659 · App. 16/224,863 · Granted Apr 28, 2020

C/EBPα short activating RNA compositions and methods of use

Inventor: PÅL SÆtrom (Trondheim, NO)
Assignee: MiNA THERAPEUTICS LIMITED
C12N15/113A61K31/7105A61K45/06A61K47/549A61K47/64C12N15/1135C12N2310/11C12N2310/113
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,633,659
App. No.
16/224,863
Granted
Apr 28, 2020
Kind
B2
Abstract

The invention relates to saRNA targeting a C/EBPα transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.

Claims (11)

1. A synthetic short activating RNA (saRNA) which up-regulates the expression of a target gene, wherein the target gene is CCAAT/enhancer-binding protein alpha (CEBPA), wherein the saRNA comprises an anti-sense strand of 19-21 nucleotides, wherein the antisense strand comprises a sequence of GACCAGUGACAAUGACCGC (SEQ ID No: 385), and wherein the antisense strand comprises at least one unpaired nucleotide at the 3′ end forming 3′ overhangs.

2. The saRNA of claim 1 , wherein the antisense strand comprises 2 unpaired nucleotides at the 3′ end forming 3′ overhangs.

3. The saRNA of claim 1 , wherein the antisense strand comprises at least one chemical modification.

4. The saRNA of claim 1 , wherein the antisense strand has a sequence of SEQ ID No: 318 or 374.

5. The saRNA of claim 1 , wherein the saRNA is double stranded and further comprises a sense strand.

6. The saRNA of claim 5 , wherein the sense strand comprises at least one chemical modification.

7. The saRNA of claim 5 , wherein the sense strand has a sequence selected from SEQ ID No: 280 or 364.

8. The saRNA of claim 1 , wherein the saRNA is double stranded and further comprises a sense strand, wherein the antisense strand comprises SEQ ID No. 318 and the sense strand comprises SEQ ID No. 280.

9. The saRNA of claim 1 , wherein the saRNA is double stranded and further comprises a sense strand, wherein the antisense strand comprises SEQ ID No. 374 and the sense strand comprises SEQ ID No. 364.

10. The saRNA of claim 1 , wherein the unpaired nucleotide is a uracil.

11. The saRNA of claim 2 , wherein the unpaired nucleotides are uracils.

Assignments (2)
SECURITY INTEREST Recorded Jan 30, 2023
From: MINA (HOLDINGS) LIMITED; MINA THERAPEUTICS LIMITED; MINA ALPHA LIMITED; MINA BETA LIMITED
To: BOOTSTRAP EUROPE 3.0 S.À R.L.
Reel/Frame 062547/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: SÆTROM, PÅL
To: MINA THERAPEUTICS LIMITED
Reel/Frame 047939/0959 →
Continuity (3)
Continuation 15038332
Provisional Application 61907732 · Nov 22, 2013
Related Publication 20190249176A1 · Aug 15, 2019